FORMULATIONS OF AN LSD1 INHIBITOR
First Claim
Patent Images
1. A pharmaceutical formulation in solid oral dosage form comprising:
- (a) an inhibitor of LSD1 which is Compound 1 di-tosylate salt of the formula;
2 Assignments
0 Petitions
Accused Products
Abstract
The present application relates to pharmaceutical formulations and dosage forms of a lysine specific demethylase-1 (LSD1) inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer.
-
Citations
38 Claims
-
1. A pharmaceutical formulation in solid oral dosage form comprising:
(a) an inhibitor of LSD1 which is Compound 1 di-tosylate salt of the formula; - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 32, 33, 34, 35, 36, 37)
-
26. A pharmaceutical formulation comprising:
-
(a) 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid di-tosylate salt (Compound 1 di-tosylate salt), or a solvate or hydrate thereof; (b) fumaric acid; and (c) lactose or mannitol, or a solvate or hydrate thereof. - View Dependent Claims (28, 29)
-
-
27. (canceled)
-
30-31. -31. (canceled)
-
38-48. -48. (canceled)
Specification